Cannell & Co’s Mereo BioPharma MREO Stock Holding History

Cannell & Co’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,025	Closed	-$26K	–	246
2019 Q2	$26K	Buy	+11,025	New	+$48.2K	﹤0.01%	236

Other funds holding MREO

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cannell & Co's MREO Position: Q3 2019 in Review

Cannell & Co sold out of Mereo BioPharma (MREO) in Q3 2019, closing a stake of 11,025 shares — an estimated $26K sold.

Cannell & Co first reported a position in MREO in Q2 2019 and held it in 1 quarter. The position peaked at $26K in Q2 2019. 16 funds tracked by Wall St. Rank hold MREO as of Q3 2019.

Cannell & Co reported no remaining Mereo BioPharma position as of Q3 2019 after selling out during the quarter.
Cannell & Co sold 11,025 Mereo BioPharma shares in Q3 2019, an estimated $26K.
Cannell & Co first reported a position in Mereo BioPharma in Q2 2019 and held it in 1 quarter.
Cannell & Co's Mereo BioPharma position peaked at $26K in Q2 2019.
16 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2019.

Based on Cannell & Co's 13F filing for Q3 2019, filed 12 Nov 2019.